| Indication | Global Market Size |
Pre Clinical |
Phase Ib |
Phase IIb |
EU Conditional Marketing Approval |
Post EU Marketing US Phase 3 |
|
|---|---|---|---|---|---|---|---|
| Organ failure associated with Sepsis | $33B | Completed | Phase IIb Initiation Q1 2021 | ||||
| ARDS associated with severe/critical COVID-19 / Non-COVID-19 ARDS | $1B (COVID) $15B (ARDS) |
Completed COVID-19 |
Phase II Ongoing COVID-19 |
||||
| Solid tumors in combination with immune checkpoints | $4B | Q3 2021 | |||||
Pipelinemonimono2021-01-28T07:27:28+00:00
